MacroGenics shares surge 20.0% intraday after CEO highlights cancer treatment breakthroughs at Evercore Healthcare Conference.

MacroGenics Inc. (NASDAQ: MGNX) surged 20.0% intraday following reports of promising breakthrough results in its cancer therapeutics, which bolstered investor confidence. The stock’s rally coincided with anticipation surrounding CEO Eric Risser’s presentation at the 8th Annual Evercore Healthcare Conference, where the company is set to highlight innovative antibody-based treatments for cancer. The news aligns with growing interest in the firm’s pipeline, despite underlying financial challenges such as a negative profit margin and high R&D costs. The intraday spike reflects heightened optimism around potential growth prospects tied to its upcoming webcast and therapeutic advancements, even as broader market scrutiny remains on the company’s profitability.